Viatris Inc. 2025 Annual Report (Form 10-K) Summary
Business Context and Reporting Period
This summary covers Viatris Inc.'s annual report for the fiscal year ended December 31, 2025. Viatris is a global healthcare company supplying generics, iconic brands, and innovative medicines to approximately 1 billion patients annually across more than 165 countries. The company operates through four segments: Developed Markets, Greater China, JANZ (Japan, Australia, New Zealand), and Emerging Markets. The reporting period reflects significant strategic shifts, including the completion of major divestitures (OTC, API, Women's Healthcare) and the initiation of an Enterprise-Wide Strategic Review (EWSR) to optimize operations for 2026.
Key Financial Metrics
| Metric | 2025 | 2024 | Change |
|---|---|---|---|
| Total Revenues | $14.30 billion | $14.74 billion | (3.0%) |
| Gross Profit | $5.01 billion | $5.62 billion | (10.8%) |
| Gross Margin | 35.0% | 38.1% | (310 bps) |
| Operating Loss | $(2.66) billion | $10.1 million | NM |
| Net Loss | $(3.51) billion | $(0.63) billion | (454%) |
| Diluted Loss Per Share | $(3.00) | $(0.53) | NM |
| Adjusted EBITDA | $4.16 billion | $4.67 billion | (10.9%) |
| Operating Cash Flow | $2.32 billion | $2.30 billion | 0.9% |
| Cash and Equivalents | $1.32 billion | $0.73 billion | 80.8% |
| Long-Term Debt | $12.48 billion | $14.04 billion | (11.1%) |
Note: "NM" indicates Not Meaningful due to sign change or magnitude.
Material Changes vs. Prior Period
- Goodwill Impairment: The primary driver of the net loss was a non-cash goodwill impairment charge of $2.94 billion recorded in Q1 2025. This was triggered by a sustained decline in share price and increased geopolitical and economic uncertainty, affecting North America, Europe, JANZ, and Emerging Markets reporting units.
- Revenue Decline: Total revenues decreased by 3% year-over-year. This was driven by the exclusion of revenue from divested businesses (OTC, API, Women's Healthcare) that closed in 2024 and the "Indore Impact" (supply disruptions at an India facility), which negatively impacted revenue by approximately $370 million.
- Divestitures: The company completed the sale of its OTC Business to Cooper Consumer Health, its API business in India to Matrix Pharma, and its women's healthcare business to Insud Pharma in 2024. In late 2025, it entered definitive agreements to sell its equity stake in Biocon Biologics for $815 million (closing in Q1 2026).
- Manufacturing Disruptions: An FDA warning letter and import alert at the Indore, India facility in 2024 continued to impact 2025 operations. Additionally, a fire in February 2026 at the Nashik, India facility temporarily suspended manufacturing, with operations expected to resume in April 2026.
Guidance, Outlook, and Risks
- Restructuring Program (EWSR): In February 2026, Viatris announced the results of its Enterprise-Wide Strategic Review. The company expects to incur total pre-tax charges between $700 million and $850 million over the next three years, including a global workforce reduction of up to 10%. Management anticipates annualized savings of $600 million to $700 million once fully implemented.
- Pipeline Progress: The company reported five positive Phase 3 data readouts in 2025, including for EFFEXOR (Japan), fast-absorbing meloxicam, a low-dose estrogen patch, and phentolamine ophthalmic solutions (LYNX-2 and VEGA-3). It also acquired Aculys Pharma to expand its CNS portfolio in Japan.
- Capital Return: In 2025, Viatris returned over $1 billion to shareholders via $500 million in share repurchases and $561 million in dividends. A quarterly dividend of $0.12 per share was declared in February 2026.
- Key Risks:
- Regulatory: Ongoing FDA remediation at the Indore facility and potential supply chain disruptions from the Nashik fire.
- Legal: Significant exposure to opioid litigation (nationwide settlement framework up to $335 million), EpiPen pricing litigation, and generic drug pricing antitrust matters.
- Financial: High indebtedness levels and the risk of further impairment charges if market conditions deteriorate.
Investor Verification Checklist
- Goodwill Impairment Assumptions: Verify the discount rates and terminal growth rates used in the Q1 2025 impairment test, as these were significantly adjusted due to macroeconomic volatility.
- Indore Facility Status: Monitor the timeline for the FDA reinspection and the lifting of the import alert, as this directly impacts revenue recovery in the Emerging Markets and Developed Markets segments.
- Restructuring Execution: Track the actual costs incurred versus the $700M-$850M estimated range for the EWSR and the realization of the projected $600M-$700M in annualized savings.
- Litigation Reserves: Review the adequacy of the $535 million accrued for legal contingencies, particularly regarding the opioid settlement and ongoing generic pricing litigation.
- Biocon Biologics Sale: Confirm the closing of the Biocon stake sale in Q1 2026 and the valuation of the equity portion of the consideration ($415 million).